Dynamic changes in serum angiopoietin-1, angiopoietin-2, and angiopoietin-2/angiopoietin-1 ratio in acute myocardial infarction patients treated with primary percutaneous coronary intervention

Biomarkers

Volumn 17, Issue 5, 2012, Pages 441-446

  Chen, Shaomin ^a   Guo, Lijun ^a   Cui, Ming ^a   Sun, Lijie ^a   Mi, Lin ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Acute myocardial infarction; Angiopoietin; Cardiovascular disease

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOPOIETIN 1; ANGIOPOIETIN 2; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TROPONIN T;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITAL ADMISSION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

AGED; ANGIOPOIETIN-1; ANGIOPOIETIN-2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME; TROPONIN T;

EID: 84864592592     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2012.684152     Document Type: Article

References (25)

1. Bijnens B, Sutherland GR. (2008). Myocardial oedema: A forgotten entity essential to the understanding of regional function after ischaemia or reperfusion injury. Heart 4:1117-1119.
2. Chen J, Yu H, Sun K, Song W, Bai Y, Yang T, Song Y, Zhang Y, Hui R. (2010). Promoter variant of angiopoietin-2 and plasma angiopoietin-2 are associated with risk of stroke recurrence in lacunar infarct patients. Biochem Biophys Res Commun 398:212-216.
3. Dallabrida SM, Ismail N, Oberle JR, Himes BE, Rupnick MA. (2005). Angiopoietin-1 promotes cardiac and skeletal myocyte survival through integrins. Circ Res 96:e8-24.
4. Di Stefano R, Felice F, Balbarini A. (2009). Angiogenesis as risk factor for plaque vulnerability. Curr Pharm Des 15:1095-1106.
5. Gu H, Cui M, Bai Y, Chen F, Ma K, Zhou C, Guo L. (2010). Angiopoietin-1/ Tie2 signaling pathway inhibits lipopolysaccharide-induced activation of RAW264.7 macrophage cells. Biochem Biophys Res Commun 392:178-182.
6. Harfouche R, Hasssian HM, Guo Y, Faivre V, Srikant CB, Yancopoulos GD, Hussain SN. (2002). Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells. Microvasc Res 64:135-147.
7. Helisch A, Schaper W. (2003). Arteriogenesis: The development and growth of collateral arteries. Microcirculation 10:83-97.
8. Iribarren C, Phelps BH, Darbinian JA, McCluskey ER, Quesenberry CP, Hytopoulos E, Vogelman JH, Orentreich N. (2011). Circulating angiopoietins-1 and -2, angiopoietin receptor Tie-2 and vascular endothelial growth factor-A as biomarkers of acute myocardial infarction: A prospective nested case-control study. BMC Cardiovasc Disord 11:31.
9. Kim I, Moon SO, Park SK, Chae SW, Koh GY. (2001). Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res 89:477-479.
10. Kolh P, Wijns W, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D; Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI). (2010). Guidelines on myocardial revascularization. Eur J Cardiothorac Surg 38 Suppl:S1-S52.
11. Lee KW, Lip GY, Blann AD. (2004). Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 110:2355-2360.
12. Lee SW, Kim WJ, Jun HO, Choi YK, Kim KW. (2009). Angiopoietin-1 reduces vascular endothelial growth factor-induced brain endothelial permeability via upregulation of ZO-2. Int J Mol Med 23:279-284.
13. Lee SW, Won JY, Lee HY, Lee HJ, Youn SW, Lee JY, Cho CH, Cho HJ, Oh S, Chae IH, Kim HS. (2011). Angiopoietin-1 protects heart against ischemia/reperfusion injury through VE-cadherin dephosphorylation and myocardiac integrin-1/ERK/caspase-9 phosphorylation cascade. Mol Med 17:1095-1106.
14. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD. (1997). Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55-60.
15. Pannitteri G, Petrucci E, Testa U. (2006). Coordinate release of angiogenic growth factors after acute myocardial infarction: Evidence of a twowave production. J Cardiovasc Med (Hagerstown) 7:872-879.
16. Patel JV, Lim HS, Varughese GI, Hughes EA, Lip GY. (2008). Angiopoietin-2 levels as a biomarker of cardiovascular risk in patients with hypertension. Ann Med 40:215-222.
17. Post S, Peeters W, Busser E, Lamers D, Sluijter JP, Goumans MJ, de Weger RA, Moll FL, Doevendans PA, Pasterkamp G, Vink A. (2008). Balance between angiopoietin-1 and angiopoietin-2 is in favor of angiopoietin-2 in atherosclerotic plaques with high microvessel density. J Vasc Res 45:244-250.
18. Ricciuto DR, dos Santos CC, Hawkes M, Toltl LJ, Conroy AL, Rajwans N, Lafferty EI, Cook DJ, Fox-Robichaud A, Kahnamoui K, Kain KC, Liaw PC, Liles WC. (2011). Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis. Crit Care Med 39:702-710.
19. Sun L, Cui M, Wang Z, Feng X, Mao J, Chen P, Kangtao M, Chen F, Zhou C. (2007). Mesenchymal stem cells modified with angiopoietin-1 improve remodeling in a rat model of acute myocardial infarction. Biochem Biophys Res Commun 357:779-784.
20. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD. (1996). Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87:1171-1180.
21. Thomas M, Augustin HG. (2009). The role of the Angiopoietins in vascular morphogenesis. Angiogenesis 12:125-137.
22. Tuo QH, Xiong GZ, Zeng H, Yu HD, Sun SW, Ling HY, Zhu BY, Liao DF, Chen JX. (2011). Angiopoietin-1 protects myocardial endothelial cell function blunted by angiopoietin-2 and high glucose condition. Acta Pharmacol Sin 32:45-51.
23. Tuo QH, Zeng H, Stinnett A, Yu H, Aschner JL, Liao DF, Chen JX. (2008). Critical role of angiopoietins/Tie-2 in hyperglycemic exacerbation of myocardial infarction and impaired angiogenesis. Am J Physiol Heart Circ Physiol 294:H2547-H2557.
24. Turer AT, Hill JA. (2010). Pathogenesis of myocardial ischemiareperfusion injury and rationale for therapy. Am J Cardiol 106:360-368.
25. Van der Heijden M, Van Nieuw Amerongen GP, Van Bezu J, Paul MA, Groeneveld AB, Van Hinsbergh VW. (2011). Opposing effects of the angiopoietins on the thrombin-induced permeability of human pulmonary microvascular endothelial cells. PLoS ONE 6:e23448.